drugset / Trial / NCT07663838

A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)

NCT07663838

Phase 1 Not yet recruiting 30 enrolled Changchun GeneScience Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

A randomized, multicenter, open-label, active-controlled Phase Ib study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of multiple intravaginal doses of GenSci142 in patients with bacterial vaginosis (BV).

Timeline

Start
2026-06-15
Primary completion
2027-01-05
Completion
2027-05-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Clindamycin Unknown 5 g Other
Subject GenSci142 Unknown Other

Indications